- Home
- NTIP vs NRSN Comparison
NTIP vs NRSN Comparison
Compare NTIP & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTIP | NRSN |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.0M | 26.4M |
| IPO Year | 1998 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NTIP | NRSN |
|---|---|---|
| Price | $1.33 | $0.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 25.3K | ★ 307.5K |
| Earning Date | 02-27-2026 | 04-06-2026 |
| Dividend Yield | ★ 7.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $150,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.16 | $0.68 |
| 52 Week High | $1.90 | $2.60 |
Technical Indicators
Market Signals| Indicator | NTIP | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 44.98 | 50.13 |
| Support Level | $1.29 | $0.92 |
| Resistance Level | $1.35 | $1.08 |
| Average True Range (ATR) | 0.04 | 0.10 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 15.38 | 54.55 |
Price Performance
Historical ComparisonAbout NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.